

Bernard L Marini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7389820/publications.pdf>

Version: 2024-02-01

81
papers

949
citations

471509

17
h-index

526287

27
g-index

84
all docs

84
docs citations

84
times ranked

1889
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Impact of number of lumens in central-venous catheters on central-line bloodstream infection (CLABSI) and venous thromboembolism (VTE) risk in patients with acute leukemia. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 125-127. | 1.8 | 2 |
| 2 | Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort study. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1315-1325. | 0.9 | 2 |
| 3 | Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 245-252. | 4.9 | 10 |
| 4 | Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials. <i>Blood Advances</i> , 2022, , . | 5.2 | 0 |
| 5 | Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1839-1848. | 1.3 | 1 |
| 6 | Oncology stewardship in acute myeloid leukemia. <i>Annals of Hematology</i> , 2022, 101, 1627-1644. | 1.8 | 2 |
| 7 | Expanding Access to CNS-TAP: Design, Development, and Initial Use of a Complex Precision Health Specialty Web App for Neuro-Oncology. <i>Studies in Health Technology and Informatics</i> , 2022, , . | 0.3 | 1 |
| 8 | Predicting CNS penetration of precision medicine therapies in oncology: A comparison of the CNS TAP tool and the BOILED-Egg computational model.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2062-2062. | 1.6 | 0 |
| 9 | Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2021, 102, 106517. | 0.8 | 4 |
| 10 | Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. <i>Leukemia and Lymphoma</i> , 2021, 62, 1990-1994. | 1.3 | 9 |
| 11 | Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts. <i>Leukemia Research</i> , 2021, 103, 106539. | 0.8 | 4 |
| 12 | Utility of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) nasal screening in patients with acute myeloid leukemia (AML). <i>Transplant Infectious Disease</i> , 2021, 23, e13612. | 1.7 | 4 |
| 13 | Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2184-2192. | 1.3 | 10 |
| 14 | Oral Azacitidine Maintenance for Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2021, 384, e51. | 27.0 | 3 |
| 15 | Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 295-308. | 0.4 | 0 |
| 16 | Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 393-400.e1. | 0.4 | 1 |
| 17 | EPCT-02. COMPARISON OF TARGETED AGENTS RECOMMENDED BY THE CNS-TAP TOOL TO THOSE SELECTED BY A TUMOR BOARD IN A MOLECULARLY-DRIVEN DIPG CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2021, 23, i46-i46. | 1.2 | 0 |
| 18 | Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 555-562. | 2.3 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-9. | 1.3 | 2 |
| 20 | Identification of variant APL translocations PRKAR1A-RAR α and ZBTB16-RAR α (PLZF-RAR α) through the MI-ONCOSEQ platform. <i>Cancer Genetics</i> , 2021, 258-259, 57-60. | 0.4 | 1 |
| 21 | Clinical Availability of ATRA for Patients With Suspected Acute Promyelocytic Leukemia: Why Guidelines May Not Be Followed. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , . | 4.9 | 2 |
| 22 | Real-World Outcomes with Immunosuppressive Therapy for Aplastic Anemia in Patients Treated at the University of Michigan. <i>Blood</i> , 2021, 138, 1126-1126. | 1.4 | 0 |
| 23 | Efficacy of HMA +/- Venetoclax or Intensive Chemotherapy in Blast-Phase Myeloproliferative Neoplasms. <i>Blood</i> , 2021, 138, 2569-2569. | 1.4 | 2 |
| 24 | Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 200-205. | 0.9 | 3 |
| 25 | Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 24-30. | 0.4 | 3 |
| 26 | Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 1126-1132. | 1.3 | 3 |
| 27 | Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 691-698. | 1.3 | 13 |
| 28 | Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 862-868. | 1.3 | 4 |
| 29 | Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1695-1702. | 0.9 | 2 |
| 30 | Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102897. | 4.4 | 2 |
| 31 | Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. <i>Current Oncology Reports</i> , 2020, 22, 19. | 4.0 | 35 |
| 32 | Everolimus improves the efficacy of dasatinib in PDGFR α -driven glioma. <i>Journal of Clinical Investigation</i> , 2020, 130, 5313-5325. | 8.2 | 41 |
| 33 | Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?. <i>Cancer</i> , 2019, 125, 3890-3891. | 4.1 | 1 |
| 34 | Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 125-138. | 4.4 | 36 |
| 35 | The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. <i>Annals of Hematology</i> , 2019, 98, 541-559. | 1.8 | 34 |
| 36 | Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz176. | 0.9 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | HGG-03. EVEROLIMUS TREATMENT IMPROVES THE CNS PENETRATION AND EFFICACY OF DASATINIB IN THE TREATMENT OF PDGFRA-DRIVEN PEDIATRIC HIGH-GRADE GLIOMA AND DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, ii87-ii87. | 1.2 | 0 |
| 38 | A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. <i>Leukemia and Lymphoma</i> , 2019, 60, 2854-2868. | 1.3 | 25 |
| 39 | PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma. <i>Lancet Oncology</i> , The, 2019, 20, e188. | 10.7 | 1 |
| 40 | Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. <i>Neuro-Oncology</i> , 2019, 21, 968-980. | 1.2 | 52 |
| 41 | Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. <i>Bone Marrow Transplantation</i> , 2019, 54, 1518-1520. | 2.4 | 18 |
| 42 | PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi186-vi186. | 1.2 | 2 |
| 43 | Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. <i>Blood Advances</i> , 2019, 3, 3333-3336. | 5.2 | 8 |
| 44 | Managing liver dysfunction in haematology patients: Switch antifungals, or use the tincture of time?. <i>Mycoses</i> , 2019, 62, 214-216. | 4.0 | 7 |
| 45 | Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 731-734. | 0.9 | 5 |
| 46 | Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML. <i>Blood</i> , 2019, 134, 2639-2639. | 1.4 | 1 |
| 47 | The effect of everolimus on CNS penetration and efficacy of dasatinib in the treatment of <i>PDGFRA</i>-driven glioma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13508-e13508. | 1.6 | 1 |
| 48 | Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1596-1605. | 1.3 | 2 |
| 49 | Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. <i>Annals of Hematology</i> , 2018, 97, 573-584. | 1.8 | 7 |
| 50 | Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 67-73. | 0.9 | 9 |
| 51 | Rational use of rasburicase for the treatment and management of tumor lysis syndrome. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 176-184. | 0.9 | 12 |
| 52 | A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 453-467. | 0.9 | 14 |
| 53 | PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 617-624. | 1.3 | 18 |
| 54 | Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1797-1806. | 1.3 | 65 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology. <i>Journal of Neuro-Oncology</i> , 2018, 137, 155-169. | 2.9 | 15 |
| 56 | Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors. <i>JCO Precision Oncology</i> , 2018, 2, 1-34. | 3.0 | 10 |
| 57 | The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. <i>Leukemia Research</i> , 2018, 70, 91-96. | 0.8 | 20 |
| 58 | Lenalidomide Plus Hypomethylating Agent for Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities -AML with Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, Mecom. <i>Blood</i> , 2018, 132, 4042-4042. | 1.4 | 0 |
| 59 | Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 255-263. | 0.9 | 3 |
| 60 | Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 502-517. | 0.9 | 4 |
| 61 | Daptomycin nonsusceptible vancomycin resistant <i>Enterococcus</i> bloodstream infections in patients with hematological malignancies: risk factors and outcomes. <i>Leukemia and Lymphoma</i> , 2017, 58, 2852-2858. | 1.3 | 20 |
| 62 | Risk factors and impact of <i>Clostridium difficile</i> recurrence on haematology patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1488-1495. | 3.0 | 28 |
| 63 | Identification and targeting of an FGFR fusion in a pediatric thalamic "central oligodendroglioma". <i>Npj Precision Oncology</i> , 2017, 1, 29. | 5.4 | 9 |
| 64 | Risk factors for subtherapeutic levels of posaconazole tablet. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2902-2905. | 3.0 | 37 |
| 65 | Catalyzing improvements in ALL therapy with asparaginase. <i>Blood Reviews</i> , 2017, 31, 328-338. | 5.7 | 37 |
| 66 | Blood-brain barrier "adapted" precision medicine therapy for pediatric brain tumors. <i>Translational Research</i> , 2017, 188, 27.e1-27.e14. | 5.0 | 12 |
| 67 | Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment. <i>Leukemia Research</i> , 2017, 63, 56-61. | 0.8 | 5 |
| 68 | Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia. <i>Supportive Care in Cancer</i> , 2017, 25, 541-547. | 2.2 | 9 |
| 69 | Real-Life Challenges to the Use of Antifungal Agents in Hematology Patients. <i>Current Fungal Infection Reports</i> , 2017, 11, 229-241. | 2.6 | 1 |
| 70 | Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 811-815. | 0.9 | 5 |
| 71 | Minimizing waste during preparation of blinatumomab infusions. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 19-20. | 1.0 | 2 |
| 72 | Therapeutic Outcomes of Patients with Acute Erythroid Leukemia Treated with Hypomethylating Agents. <i>Blood</i> , 2016, 128, 5203-5203. | 1.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Characterizing and targeting <i>PDGFRA</i> alterations in pediatric high-grade glioma. <i>Oncotarget</i> , 2016, 7, 65696-65706. | 1.8 | 55 |
| 74 | Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1115-1115. | 1.5 | 7 |
| 75 | Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. <i>Mycoses</i> , 2015, 58, 432-436. | 4.0 | 53 |
| 76 | Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia. <i>Supportive Care in Cancer</i> , 2015, 23, 2287-2295. | 2.2 | 6 |
| 77 | Risk for Invasive Fungal Infections during Acute Myeloid Leukemia Induction Therapy: a True Association with Echinocandins?. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4988-4989. | 3.2 | 3 |
| 78 | The effects of an informational video on patient knowledge, satisfaction and compliance with venous thromboembolism prophylaxis: A pilot study. <i>Patient Education and Counseling</i> , 2014, 96, 264-267. | 2.2 | 29 |
| 79 | Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. <i>Anticancer Research</i> , 2012, 32, 2391-8. | 1.1 | 3 |
| 80 | “VTE and You”: Assessment of a VTE Patient Education Video (InPHARMmercial) and an Electronic Risk Scoring Tool in Hospitalized Medicine Patients. <i>Chest</i> , 2011, 140, 592A. | 0.8 | 0 |
| 81 | Role of T Cell TGF β Signaling and IL-17 in Allograft Acceptance and Fibrosis Associated with Chronic Rejection. <i>Journal of Immunology</i> , 2009, 183, 7297-7306. | 0.8 | 59 |